Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Page 1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
JAMA. 2023.
PMID: 37459141
Free PMC article.
Participants in the donanemab group were switched to receive placebo in a blinded manner if dose completion criteria were met. ...Three deaths in the donanemab group and 1 in the placebo group were considered treatment related. ...
Participants in the donanemab group were switched to receive placebo in a blinded manner if dose completion criteria were met. ...Thr …
Use of Donanemab in Early Symptomatic Alzheimer Disease.
Pomara N, Imbimbo BP.
Pomara N, et al.
JAMA. 2023 Dec 19;330(23):2304. doi: 10.1001/jama.2023.21106.
JAMA. 2023.
PMID: 38112820
No abstract available.
Item in Clipboard
Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
Evans CD, Sims JR.
Evans CD, et al.
JAMA. 2023 Dec 19;330(23):2304-2305. doi: 10.1001/jama.2023.21109.
JAMA. 2023.
PMID: 38112817
No abstract available.
Item in Clipboard
Cite
Cite